Original research articleFirst-time use of newer oral contraceptives and the risk of venous thromboembolism☆
References (22)
- et al.
Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen
Lancet
(1995) - et al.
Population-based study of risk of venous thromboembolism associated with various oral contraceptives
Lancet
(1997) - et al.
Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestogen components [see also comments]
Lancet
(1995) - et al.
End of the line for “third-generation-pill” controversy?
Lancet
(1997) - et al.
Oral contraceptives and thrombotic diseases: impact of new epidemiological studies
Contraception
(1996) - et al.
The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observational research
Contraception
(1996) Behavior of the exposure odds ratio in a case-control study when the hazard function is not constant over time
J Clin Epidemiol
(1989)- et al.
Principles of non-experimental assessment of excess risk, with special reference to adverse drug reactions
J Clin Epidemiol
(1989) The evolution of clinical practice and time trends in drug effects
J Clin Epidemiol
(1994)- et al.
Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study
Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study
Cited by (187)
Comparison of estrogenic components used for hormonal contraception
2024, ContraceptionTolerability and safety of the estetrol/drospirenone combined oral contraceptive: Pooled analysis of two multicenter, open-label phase 3 trials
2022, ContraceptionCitation Excerpt :The overall estimated annual VTE incidence rate across the full E4/DRSP clinical program (pooled phase 2 and 3 trials) is 3.66/10,000 woman-years [31]. The risk of VTE is considered highest in the first 12 months of using a new COC [32], with multiple studies reporting a small increased risk in new users compared to switchers [32–34], perhaps because switchers have already demonstrated a lower risk for VTE [34]. A similar increased risk has also been observed in those re-starting a COC after an absence [35].
Antiandrogens and Androgen Inhibitors
2020, Comprehensive Dermatologic Drug Therapy, Fourth EditionWomen, thrombosis, and cancer
2019, Thrombosis Research
- ☆
Funded in part by grants from Organon, Schering AG, and the Fonds de la Recherche en Santé du Québec (FRSQ). Samy Suissa is a Senior Research Scholar of the FRSQ. Lucie Blais is the recipient of a doctoral scholarship from the National Health and Development Program of Canada (NHRDP). The McGill Pharmacoepidemiology Research Unit is funded by the FRSQ.